Continued strong momentum with second-quarter sales growth of 23% on a reported basis and strong adjusted margin expansion Reported second-quarter net loss from continuing operations of $0.34 per share with adjusted net income per diluted share of$0.62 Advanced strategic goals with solid first half of 2024, slightly ahead of expectations, and set up to accelerate in the second half of the year Wilmington, DE, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical t ...